Radiation with immunotherapy and targeted therapy for liver cancer with portal vein clot
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation therapy, an immunotherapy drug (tislelizumab), and a targeted therapy drug (anlotinib) for people with liver cancer that has spread into the main blood vessel of the liver (portal vein). The goal is to see if this combination can shrink or control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old and have been diagnosed with hepatocellular carcinoma (liver cancer) that has a tumor clot in the portal vein (a major blood vessel in the liver).
- Your cancer must not be removable with surgery at this time.
- You cannot have received any previous cancer treatment for this disease.
- You need to be in generally good health, able to perform daily activities, and have a Child-Pugh liver function score of A (meaning your liver is working fairly well).
- You need to have at least one tumor that can be measured on scans, and you must provide a tumor tissue sample if possible.
- You must not have a history of autoimmune diseases, recent heart problems, active tuberculosis, or have been treated with other experimental drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests whether giving two medicines (an immunotherapy and a targeted therapy) after surgery can help prevent liver cancer from coming back in people with a specific type of tumor clot in the liver's main vein. If you've had surgery to remove the cancer and meet the health criteria, this treatment may lower your risk of recurrence.
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.